Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01251978 · ClinicalTrials.gov registry record · Phase 2
Ranibizumab as Adjuvant Therapy for the Treatment of Choroidal Melanoma (Cohort 2)
A Phase 2 study of Choroidal Melanoma, sponsored by New England Retina Associates.
- Completed
- Registry status
- Phase 2
- Development phase
- 10
- Enrollment target
- 1
- Study location
NCT01251978: Completed Phase 2 study of Choroidal Melanoma, sponsored by New England Retina Associates.
NCT01251978 is a Phase 2 study of Choroidal Melanoma that has completed, run by New England Retina Associates. The registered enrollment target is 10 participants, below the 213-participant average among 3 other Choroidal Melanoma trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01251978, a Phase 2 study of Choroidal Melanoma, has completed, sponsored by New England Retina Associates.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 10 participants
- Enrollment target
- 1
- Study location
Study Summary
Ranibizumab has proven to be of benefit to improve the perfusion in the retina of patients with Choroidal Melanoma. The investigators consider that higher doses of Ranibizumab can help reduce the number of laser treatments that might be needed to control the tumor.
Conditions Studied
Interventions
- DRUG Ranibizumab 2 mg
- DRUG 0.5 mg Ranibizumab
Study Locations (1)
Connecticut
- New England Retina Associates - Hamden
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2010-07 |
| Est. Completion | 2012-08 |
| Phase | Phase 2 |
What the finished NCT01251978 record still lists
NCT01251978 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 10 participants, a relatively small participant target, below the 213-participant average among 3 other Choroidal Melanoma trials with a reported enrollment target (95% lower).
The record links to 1 condition, with Choroidal Melanoma appearing as the primary indexed condition, and to 2 interventions - of which Ranibizumab 2 mg is the first listed.
NCT01251978 reports a single indexed study location in Connecticut.
Frequently Asked Questions
What is clinical trial NCT01251978 about?
NCT01251978 is a clinical study titled "Ranibizumab as Adjuvant Therapy for the Treatment of Choroidal Melanoma (Cohort 2)". Ranibizumab has proven to be of benefit to improve the perfusion in the retina of patients with Choroidal Melanoma. The investigators consider that higher doses of Ranibizumab can help reduce the number of laser treatments that might be needed to control the tumor.
What is the current status of trial NCT01251978?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 10 participants. The study started on 2010-07. Estimated completion is 2012-08.
What conditions does trial NCT01251978 study?
This clinical trial studies the following conditions: Choroidal Melanoma.
What interventions are being tested in trial NCT01251978?
The interventions under investigation include: Ranibizumab 2 mg (DRUG), 0.5 mg Ranibizumab (DRUG).
Who is sponsoring clinical trial NCT01251978?
This trial is sponsored by New England Retina Associates, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01251978 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Choroidal Melanoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Registry of Subjects With Primary Indeterminate Lesions or Choroidal Melanoma
RECRUITING
-
A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal Melanoma
RECRUITING · Phase 3
-
Ranibizumab in Combination With Proton Beam Irradiation for Choroidal Melanoma
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00623389 · 10 participants · NA
Evaluation of an Advanced Lower Extremity Neuroprostheses
- NCT01241864 · 10 participants · Phase 2
Islet Transplantation in Type 1 Diabetic Kidney Allograft
- NCT01293214 · 10 participants · NA
Vascularized Composite Allotransplantation for Multiple Extremity Amputations
- NCT01474148 · 10 participants · NA
A Neuroprosthesis for Seated Posture and Balance
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia